OraPharma Launches ARESTIN Student Access Program

OraPharma, Inc., maker of ARESTINR (minocycline hydrochloride) Microspheres,
1 mg, recently introduced the ARESTINR Student Access Program for dental and
hygiene schools. The program, which is scheduled to begin in September, is
open to all accredited two- or four-year dental and dental hygiene schools
that include instruction on the use of ARESTINR as part of a comprehensive
Periodontal Treatment Protocol. The launch of this program marks the first
time that ARESTINR will be widely available for clinical use by dental and
hygiene school students.

Read the press release